1 / 17

AGGRENOX TM Development Rationale

AGGRENOX TM Development Rationale . Thomas Müller, MD, PhD. Head of Haemostasis Laboratory Blood Transfusion Center of the German Red Cross Oldenburg, Germany. Haemostatic Repair. Mural Thrombus Formation. Platelet Aggregates Form Under Flow on Subendothelial Matrix. Flow. Blood

aspasia
Télécharger la présentation

AGGRENOX TM Development Rationale

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. AGGRENOXTMDevelopment Rationale Thomas Müller, MD, PhD Head of Haemostasis Laboratory Blood Transfusion Center of the German Red Cross Oldenburg, Germany

  2. Haemostatic Repair

  3. Mural Thrombus Formation

  4. Platelet Aggregates Form Under Flow on Subendothelial Matrix Flow Blood Sample (anticoagulated) Formation of Platelet Aggregates Müller et al. (1990) Br J Clin Pharmac.

  5. Inhibition of the Growthof All Aggregates 80 N = 24 N = 23 60 Relative Reduction in Mean Area of ALL Thrombi (%) 40 N = 22 20 N = 23 0 Placebo ER-DP 400 mg/d ASA 50 mg/d ASA/ER-DP 50 mg + 400 mg/d Müller et al. (1990) Br J Clin Pharmac.

  6. Inhibition of the Growthof Very Large Aggregates 4 3 Reduction ofVERY LARGE Thrombi 2 1 0 Placebo ASA/ER-DP50 mg + 400 mg/d ER-DP400 mg/d ASA50 mg/d Müller et al. (1990) Br J Clin Pharmac.

  7. Mural Thrombus Formation

  8. Cyclooxygenase Generates Thromboxane A2 TxA2 AA

  9. ASA Irreversibly Inhibits Cyclooxygenase TxA2 AA X AA 40 mg ASA/d in stroke patients Weksler B et al. (1985) Stroke. 16:1–9.

  10. ASA Inhibits Only a Single of Multiple Pathways TxA2 Collagen Thrombin Shear Adrenaline PAF X ADP ? Platelet Activation Aggregation

  11. ADP is Degraded to Adenosine ADP Adenosine

  12. DP Inhibits the Adenosine UptakeIC50 = 0.25 µg/mL Human Plasma Platelet Inhibition X ADP Adenosine

  13. Extended Release Dipyridamole 2.5 2.0 DP Plasma Conc. (µg/mL) 1.5 1.0 0.5 0 4 8 12 Time (hours)

  14. Summary and Conclusions • Dipyridamole and ASA inhibit platelet aggregation by independent mechanisms • Doses and formulations • No evidence for pharmacokinetic interaction

  15. Summary and Conclusions • Dipyridamole and ASA inhibit platelet aggregation by independent mechanisms • Doses and formulations optimized • No evidence for pharmacokinetic interaction • Combining ASA with DP in AGGRENOXTM • Additive inhibition of platelet thrombus formation

More Related